133 related articles for article (PubMed ID: 22248133)
21. [Parkinson's disease].
Yokochi M
Ryoikibetsu Shokogun Shirizu; 1999; (27 Pt 2):5-14. PubMed ID: 10434578
[No Abstract] [Full Text] [Related]
22. [Treatment of parkinsonism and legal capacity].
Wallesch CW
Fortschr Neurol Psychiatr; 2011 Aug; 79(8):441. PubMed ID: 21809256
[No Abstract] [Full Text] [Related]
23. [Levodopa dependency in Parkinson's disease: case report and review].
Müller U; Reuter M; Hermann W; Gertz HJ
Nervenarzt; 2002 Sep; 73(9):887-91. PubMed ID: 12215883
[TBL] [Abstract][Full Text] [Related]
24. [Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine].
Montastruc JL; Schmitt L; Bagheri H
Rev Neurol (Paris); 2003 Apr; 159(4):441-3. PubMed ID: 12773874
[TBL] [Abstract][Full Text] [Related]
25. Dopamine dysregulation syndrome in Parkinson's disease: case report.
Kummer A; Maia DP; Salgado JV; Cardoso FE; Teixeira AL
Arq Neuropsiquiatr; 2006 Dec; 64(4):1019-22. PubMed ID: 17221016
[TBL] [Abstract][Full Text] [Related]
26. Recent advances in pharmacological therapy of Parkinson's disease.
Riederer P; Lange KW; Youdim MB
Adv Neurol; 1993; 60():626-35. PubMed ID: 8093582
[TBL] [Abstract][Full Text] [Related]
27. [Behavioral disorders in Parkinson's disease: from pathophysiology to the mastery of dopaminergic treatment].
Thobois S; Ardouin C; Schmitt E; Lhommée E; Klinger H; Xie J; Lagrange C; Kistner A; Aya Kombo M; Fleury V; Poisson A; Fraix V; Broussolle E; Pollak P; Krack P
Rev Neurol (Paris); 2010 Oct; 166(10):816-21. PubMed ID: 20739041
[TBL] [Abstract][Full Text] [Related]
28. Resolution of dopamine dysregulation syndrome following cessation of dopamine agonist therapy in Parkinson's disease.
Kimber TE; Thompson PD; Kiley MA
J Clin Neurosci; 2008 Feb; 15(2):205-8. PubMed ID: 18068992
[TBL] [Abstract][Full Text] [Related]
29. [Hypersexuality during use of levodopa].
van Deelen RA; Rommers MK; Eerenberg JG; Egberts AC
Ned Tijdschr Geneeskd; 2002 Nov; 146(44):2095-8. PubMed ID: 12448966
[TBL] [Abstract][Full Text] [Related]
30. Recent advances in Parkinson's disease.
Vécsei L
Ideggyogy Sz; 2002 Nov; 55(11-12):406-7. PubMed ID: 12632802
[No Abstract] [Full Text] [Related]
31. Hypersexuality due to dopaminergic drugs.
Prescrire Int; 2005 Dec; 14(80):224. PubMed ID: 16400746
[TBL] [Abstract][Full Text] [Related]
32. Dopaminergic dysregulation syndrome in Parkinson's disease.
Katzenschlager R
J Neurol Sci; 2011 Nov; 310(1-2):271-5. PubMed ID: 21868039
[TBL] [Abstract][Full Text] [Related]
33. Clinical pharmacology of levodopa-induced dyskinesia in parkinsonian patients.
Rascol O; Brefel-Courbon C; Descombes S; Montastruc JL
Adv Neurol; 1999; 80():485-90. PubMed ID: 10410760
[No Abstract] [Full Text] [Related]
34. Levodopa addiction in idiopathic Parkinson disease.
Borek LL; Friedman JH
Neurology; 2005 Nov; 65(9):1508. PubMed ID: 16275855
[No Abstract] [Full Text] [Related]
35. [Drug therapy of Parkinson's disease].
Myllylä V
Duodecim; 1997; 113(18):1827-34. PubMed ID: 10892076
[No Abstract] [Full Text] [Related]
36. Progress in Parkinson's disease.
Schapira AH
Eur J Neurol; 2008 Jan; 15(1):1. PubMed ID: 18171385
[No Abstract] [Full Text] [Related]
37. Dopamine asymmetry interacts with medication to affect cognition in Parkinson's disease.
Tomer R; Aharon-Peretz J; Tsitrinbaum Z
Neuropsychologia; 2007 Jan; 45(2):357-67. PubMed ID: 16876208
[TBL] [Abstract][Full Text] [Related]
38. [Assessment of hyper- and hypodopaminergic behaviors in Parkinson's disease].
Ardouin C; Chéreau I; Llorca PM; Lhommée E; Durif F; Pollak P; Krack P;
Rev Neurol (Paris); 2009 Nov; 165(11):845-56. PubMed ID: 19683776
[TBL] [Abstract][Full Text] [Related]
39. Treatment of Parkinson's disease--where do we go from here?
Suchowersky O
Nat Clin Pract Neurol; 2006 Sep; 2(9):461. PubMed ID: 16932605
[No Abstract] [Full Text] [Related]
40. Sleep disorders in Parkinson's disease.
Larsen JP
Adv Neurol; 2003; 91():329-34. PubMed ID: 12442690
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
